Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment
- PMID: 14638544
- DOI: 10.1161/01.CIR.0000103624.14436.4B
Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment
Abstract
Background: The inflammatory/antiinflammatory properties of HDL were compared with HDL cholesterol in 2 groups of patients and in age- and sex-matched control subjects.
Methods and results: Group 1 consisted of 26 patients not yet taking a statin who presented with coronary heart disease (CHD) or CHD equivalents by National Cholesterol Education Program Adult Treatment Panel III criteria studied before and 6 weeks after 40 mg/d of simvastatin. Group 2 consisted of 20 patients with documented CHD and HDL cholesterol > or =84 mg/dL. The inflammatory/antiinflammatory properties of HDL were determined by the ability of the subject's HDL to alter LDL-induced monocyte chemotactic activity (MCA) in a human artery wall coculture. Induction of MCA by a control LDL was determined in the absence or presence of the subject's HDL. Values in the absence of HDL were normalized to 1.0. Values >1.0 after the addition of HDL indicated proinflammatory HDL; values <1.0 indicated antiinflammatory HDL. Group 1 values before simvastatin were LDL cholesterol, 118+/-24 mg/dL; HDL cholesterol, 57+/-13 mg/dL; triglycerides, 125+/-64 mg/dL; and high-sensitivity C-reactive protein (hs-CRP), 1.7+/-1.9 mg/L; and MCA values were 1.38+/-0.91, compared with 0.38+/-0.14 for control subjects (P=1.5x10(-5)). After simvastatin, values were LDL cholesterol, 73+/-24 mg/dL; HDL cholesterol, 61+/-14 mg/dL; triglycerides, 99+/-52 mg/dL; and hs-CRP, 1.3+/-1.3 mg/L; and MCA values were 1.08+/-0.71. In group 2, values were LDL cholesterol, 108+/-34 mg/dL; HDL cholesterol, 95+/-14 mg/dL; triglycerides, 89+/-44 mg/dL; and hs-CRP, 0.8+/-0.7 mg/L; and MCA values were 1.28+/-0.29, compared with 0.35+/-0.11 for control subjects (P=1.7x10(-14)). Similar results were obtained with the cell-free assay.
Conclusions: The inflammatory/antiinflammatory properties of HDL distinguished patients from control subjects better than HDL cholesterol and were improved with simvastatin.
Similar articles
-
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.Diabetes Obes Metab. 2005 Jul;7(4):430-8. doi: 10.1111/j.1463-1326.2004.00450.x. Diabetes Obes Metab. 2005. PMID: 15955130
-
Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.Kardiol Pol. 2004 Jun;60(6):567-77. Kardiol Pol. 2004. PMID: 15334157 English, Polish.
-
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.Curr Med Res Opin. 2003;19(8):689-98. doi: 10.1185/030079903125002405. Curr Med Res Opin. 2003. PMID: 14687438 Clinical Trial.
-
High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.Am Heart J. 2002 Dec;144(6 Suppl):S33-42. doi: 10.1067/mhj.2002.130301. Am Heart J. 2002. PMID: 12486414 Review.
-
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.Curr Med Res Opin. 2006 Mar;22(3):511-28. doi: 10.1185/030079906X89856. Curr Med Res Opin. 2006. PMID: 16574035 Review.
Cited by
-
All in the family: The link between kin network bridging and cardiovascular risk among older adults.Soc Sci Med. 2016 Oct;166:137-149. doi: 10.1016/j.socscimed.2016.07.035. Epub 2016 Jul 28. Soc Sci Med. 2016. PMID: 27566043 Free PMC article.
-
HDL, Atherosclerosis, and Emerging Therapies.Cholesterol. 2013;2013:891403. doi: 10.1155/2013/891403. Epub 2013 May 28. Cholesterol. 2013. PMID: 23781332 Free PMC article.
-
The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.Lipids Health Dis. 2015 Apr 16;14:29. doi: 10.1186/s12944-015-0031-4. Lipids Health Dis. 2015. PMID: 25885289 Free PMC article.
-
Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit?Curr Atheroscler Rep. 2010 Jan;12(1):14-9. doi: 10.1007/s11883-009-0085-8. Curr Atheroscler Rep. 2010. PMID: 20425266 Review.
-
Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.J Lipid Res. 2011 Feb;52(2):361-73. doi: 10.1194/jlr.M011098. Epub 2010 Nov 10. J Lipid Res. 2011. PMID: 21068008 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous